D-2 dopamine-receptors regulate the release of [3H]dopamine in rat cortical regions showing dopamine immunoreactive fibers

[1]  B. Westerink.  Sequence and significance of dopamine metabolism in the rat brain , 1985, Neurochemistry International.

[2]  J. C. Stoof,et al.  Stimulation of D-2 dopamine receptors in rat mesocortical areas inhibits the release of [3H]dopamine. , 1985, European journal of pharmacology.

[3]  B. Berger,et al.  New dopaminergic terminal fields in the motor, visual (area 18b) and retrosplenial cortex in the young and adult rat. Immunocytochemical and catecholamine histochemical analyses , 1985, Neuroscience.

[4]  J. Kebabian,et al.  TL 333, a benzhydro[g]quinoline, stimulates both D-1 and D-2 dopamine receptors: implications for the selectivity of LY 141865 towards the D-2 receptor. , 1985, European journal of pharmacology.

[5]  J. C. Stoof,et al.  Two dopamine receptors: biochemistry, physiology and pharmacology. , 1984, Life sciences.

[6]  J. Kebabian,et al.  N,N-disubstituted 2-aminotetralins are potent D-2 dopamine receptor agonists. , 1984, European journal of pharmacology.

[7]  R. Roth.  CNS Dopamine Autoreceptors: Distribution, Pharmacology, and Function a , 1984, Annals of the New York Academy of Sciences.

[8]  R. Roth,et al.  Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons , 1984, Neuroscience.

[9]  D. Sarkar,et al.  Uptake and release of [3H]dopamine by the median eminence: Evidence for presynaptic dopaminergic receptors and for dopaminergic feedback inhibition , 1983, Neuroscience.

[10]  R. Roth,et al.  Pharmacology of dopamine neurons innervating the prefrontal, cingulate and piriform cortices. , 1983, European journal of pharmacology.

[11]  R. Roth,et al.  Pharmacology of mesocortical dopamine neurons. , 1983, Pharmacological reviews.

[12]  J. C. Stoof,et al.  Stimulation of D2-dopamine receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect the release of gamma-aminobutyric acid, glutamate or serotonin. , 1982, European journal of pharmacology.

[13]  M. Bitran,et al.  On the mechanism of presynaptic autoreceptor-mediated inhibition of transmitter synthesis in dopaminergic nerve terminals. , 1982, Biochemical pharmacology.

[14]  R. Roth,et al.  Unique response to antipsychotic drugs is due to absence of terminal autoreceptors in mesocortical dopamine neurones , 1982, Nature.

[15]  G. Gessa,et al.  N-n-propyl-norapomorphine: An extremely potent stimulant of dopamine autoreceptors , 1982, Brain Research.

[16]  S. Z. Langer,et al.  Stereoselectivity of presynaptic autoreceptors modulating dopamine release. , 1981, European journal of pharmacology.

[17]  N. Bacopoulos.  Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies. , 1981, The Journal of pharmacology and experimental therapeutics.

[18]  J. Kebabian,et al.  Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor , 1981, Nature.

[19]  R. Roth,et al.  Mesocortical dopamine neurons. Lack of autoreceptors modulating dopamine synthesis. , 1981, Molecular pharmacology.

[20]  C. Carter,et al.  Effect of 6‐Hydroxydopamine Lesions of the Medial Prefrontal Cortex on Neurotransmitter Systems in Subcortical Sites in the Rat , 1980, Journal of neurochemistry.

[21]  L. Sokoloff,et al.  Specific distribution of metabolic alterations in cerebral cortex following apomorphine administration , 1979, Nature.

[22]  J. Glowinski,et al.  Topographical distribution of dopaminergic innervation and dopaminergic receptors of the anterior cerebral cortex of the rat , 1978, Brain Research.

[23]  H. Sarau,et al.  The central effects of a novel dopamine agonist. , 1978, European journal of pharmacology.

[24]  G. Koob,et al.  The origin and distribution of dopamine-containing afferents to the rat frontal cortex , 1978, Brain Research.

[25]  K. Starke,et al.  Presynaptic receptor systems in catacholamingergic transmission. , 1977, Biochemical pharmacology.

[26]  J. Walters,et al.  Dopamine in substantia nigra and cortex after γ‐butyrolactone treatment , 1976 .

[27]  P. Spano,et al.  Sulpiride: a study of the effects on dopamine receptors in rat neostriatum and limbic forebrain. , 1975, Life sciences.

[28]  O. Johansson,et al.  Dopamine Nerve Terminals in the Rat Limbic Cortex: Aspects of the Dopamine Hypothesis of Schizophrenia , 1974, Science.

[29]  T. Magnusson,et al.  Individual elution of noradrenaline (together with adrenaline), dopamine, 5‐hydroxytryptamine and histamine from a single, strong cation exchange column, by means of mineral acid‐organic solvent mixtures , 1970, The Journal of pharmacy and pharmacology.

[30]  L. Sternberger,et al.  THE UNLABELED ANTIBODY ENZYME METHOD OF IMMUNOHISTOCHEMISTRY PREPARATION AND PROPERTIES OF SOLUBLE ANTIGEN-ANTIBODY COMPLEX (HORSERADISH PEROXIDASE-ANTIHORSERADISH PEROXIDASE) AND ITS USE IN IDENTIFICATION OF SPIROCHETES , 1970, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[32]  D. Haubrich,et al.  The autoreceptor control of dopamine synthesis. An in vitro and in vivo comparison of dopamine agonists. , 1982, Molecular pharmacology.

[33]  R. Roth,et al.  Chronic haloperidol or fluphenazine: effects on dopamine metabolism in brain, cerebrospinal fluid and plasma of Cercopithecus aethiops (vervet monkey). , 1980, The Journal of pharmacology and experimental therapeutics.